Supplementary material to article by G. Yosipovitch et al. “Secukinumab Provides Rapid Relief From Itching and Pain in Patients With Moderate-to-Severe Psoriasis: Patient Symptom Diary Data From Two Phase 3, Randomized, Placebo-Controlled Clinical Trials”

Fig. S1. Absolute mean (SE) change from baseline in Psoriasis Symptom Diary (a) itching severity and (b) pain severity scores and proportions of patients who achieved scores of 0 or 1 for (c) itching severity and (d) pain severity (ITT population). For each postbaseline visit, only patients with values at both baseline and the respective postbaseline visit were included. Missing data were imputed using the last observation carried forward method. All analyses were for hypothesis generation only. Error bars represent standard errors. *p < 0.05 vs placebo; **p < 0.05 vs placebo and etanercept; ***p < 0.05 vs placebo, etanercept, and secukinumab 150 mg. **Question: “Overall, how severe was your psoriasis-related itching over the past 24 h?” (0 = no itching; 10 = itching as bad as you can imagine). *Question: “Overall, how severe was your psoriasis-related pain over the past 24 h?” (0 = no pain; 10 = pain as bad as you can imagine).